Monitoring the acute phase response: comparison of tumour necrosis factor (cachectin) and C-reactive protein responses in inflammatory and infectious diseases.
Open Access
- 1 October 1989
- journal article
- research article
- Published by BMJ in Journal of Clinical Pathology
- Vol. 42 (10) , 1078-1082
- https://doi.org/10.1136/jcp.42.10.1078
Abstract
The relation between the inflammatory cytokine tumour necrosis factor-alpha (TNF or cachectin), which induces acute phase responses, and an established acute phase protein, C-reactive protein, was studied in various infectious and inflammatory diseases in man. All cases with very high serum concentrations of C-reactive protein (150 to 400 mg/l; normal reference value less than 10 mg/l) also had raised serum concentrations of TNF (53 to 705 ng/l; normal reference value less than 40 ng/l). In 19 out of 91 (21%) of the cases, however, a raised TNF concentration without correspondingly raised C-reactive protein concentration was also noted. Conversely, in 23 out of 106 (22%) cases raised C-reactive protein was observed in the absence of a raised TNF concentration. The ratios were high in allograft rejection and low in myocardial infarction and Kawasaki's disease. The highest mean concentration of circulating TNF was found in bacterial infections, graft rejection, and myocardial infarction. It is concluded that although high C-reactive protein concentrations are usually accompanied by raised TNF concentrations, there are pronounced relative variations in the serum concentrations of these proteins in various disease states, suggesting that there may be independent, disease specific regulatory pathways for TNF and C-reactive protein.This publication has 34 references indexed in Scilit:
- Recombinant human interleukin‐6 (IL‐6/BSF‐2/HSF) regulates the synthesis of acute phase proteins in human hepatocytesPublished by Wiley ,2001
- Circulating tumour necrosis factor‐α (cachectin) in myocardial infarctionJournal of Internal Medicine, 1989
- DETECTION OF CIRCULATING TUMOUR NECROSIS FACTOR IN SYSTEMIC HISTIOCYTOSISBritish Journal of Haematology, 1989
- Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs.-host disease.The Journal of Experimental Medicine, 1987
- Single germline VH and V kappa genes encode predominating antibody variable regions elicited in strain A mice by immunization with p-azophenylarsonate.The Journal of Experimental Medicine, 1987
- ASSOCIATION BETWEEN TUMOUR NECROSIS FACTOR IN SERUM AND FATAL OUTCOME IN PATIENTS WITH MENINGOCOCCAL DISEASEThe Lancet, 1987
- Tumour Necrosis Factor—an OverviewActa Medica Scandinavica, 1986
- Human High-density Lipoprotein Associated Amyloid a Protein: Structural Characteristics, Relation to Apo A-I and A-II Concentrations, and Plasma Clearance Kinetics in the RatScandinavian Journal of Rheumatology, 1985
- Plasma clearance kinetics of the amyloid-related high density lipoprotein apoprotein, serum amyloid protein (apoSAA), in the mouse. Evidence for rapid apoSAA clearance.Journal of Clinical Investigation, 1983
- ESTIMATION OF IN VIVO RATES OF C‐REACTIVE PROTEIN SYNTHESIS FROM SERUM TURNOVER STUDIES IN RABBITS*Annals of the New York Academy of Sciences, 1982